Publications by authors named "Carine Saadoun"
Introduction: Guselkumab is a human monoclonal antibody against IL-23 used in the treatment of moderate-to-severe psoriasis. This post-hoc analysis evaluated the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years.
Methods: The proportions of guselkumab-treated Asian patients (VOYAGE 1 and 2) achieving Psoriasis Area and Severity Index (PASI) 90 and PASI 100, Investigator's Global Assessment (IGA) scores of 0/1 and 0, and Dermatology Life Quality Index (DLQI) scores of 0/1 (week 100 through week 252) were assessed.
Article Synopsis
- Patients with psoriasis were randomly assigned to receive either guselkumab, adalimumab, or a placebo in the VOYAGE 1 and VOYAGE 2 studies, focusing on difficult-to-treat psoriasis areas in an Asian subpopulation.
- At week 24, guselkumab showed significantly better results compared to adalimumab in achieving "clear" or "near clear" scores for scalp and hands/feet psoriasis, while improvements in nail psoriasis were similar between the two treatments.
- The study also indicated that guselkumab was more effective regardless of whether patients had prior biologic treatment, matching the results of the larger global population.
Background: Biologics are used to treat moderate-to-severe Crohn disease (CD). In Japan, ustekinumab was approved for reimbursement for CD treatment in 2017. However, limited information describes utilization of ustekinumab in real-world settings.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness and adherence to biologics for treating moderate-to-severe psoriasis in Taiwan using data from the National Health Insurance Research Database.
- A total of 1,397 patients were analyzed, revealing that ustekinumab had the highest persistence rates (94.2% at 1 year and 84.9% at 2 years) compared to adalimumab and etanercept.
- Results indicated that patients on ustekinumab had a significantly lower risk of treatment discontinuation than those on adalimumab and etanercept, highlighting its potential as a preferred treatment option.
Objectives: To compare different early clinical criteria of non-response determined at three months as predictors of clinical failure at one year in patients with rheumatoid arthritis starting therapy with certolizumab pegol.
Methods: Data were derived from a randomised Phase III clinical trial in patients with rheumatoid arthritis who failed to respond to methotrexate monotherapy. Patients included in this post-hoc analysis were treated with certolizumab pegol (400mg qd reduced to 200mg qd after one month) and with methotrexate.
Objectives: To evaluate the cost-effectiveness of a Treat-to-Target strategy with certolizumab pegol in patients with rheumatoid arthritis in the context of a pay-for-performance agreement in which medication costs are refunded in case of discontinuation during the first 3 months of treatment.
Methods: The Treat-to-Target strategy consisted of a systematic switch to second-line tumor necrosis factor (TNF)α inhibitor in case of an unmet ACR50 response at 3 months compared to current routine clinical practice. A reference cohort treated first-line with certolizumab pegol according to current practice without systematic switching was considered as the comparator.